Top 25 Life Science Startup Investors in Norway (July 2026)

Portfolio highlights

• Sonair — Sonair is an award-winning deep tech startup building a breakthrough, patented 3D ultrasonic sensor that enables true machine autonomy by making robots safe, affordable, and efficient. Sonair was spun out from a leading European independent research organization, SINTEF, to exploit deep science-to-tech advancements in ultrasonics andMicro-ElectroMechanical Systems (MEMS). Using this technology, the company is delivering a sensor that will transform a robot’s vision from 2D to 3D, offering a significantly improved safety performance over traditional vision systems while cutting costs by 50-80%. The company, based in Oslo, Norway, was founded in 2022 by an experienced team of serial entrepreneurs led by Knut Sandven, former CEO of GasSecure.
• Two — Buy Now, Pay Later for your business customers. Two makes it easy and safe to offer invoice as a payment method on your e-commerce site.
• Muybridge — Reimagining cameras with weightless software-based viewpoint

Portfolio highlights

• Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
• Porterbuddy — They are the gang that delivers to your door the same day you order in the online store.Porterbuddy'​ is a logistics platform that provides efficient and customer-centric, last-mile delivery of products.
• Galecto — Damora Therapeutics is working to fundamentally redefine care for people with blood disorders by bringing forward optimized therapies that dramatically improve patient outcomes.

Portfolio highlights

• iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
• Future Fertility — OUR AI-POWERED ASSESSMENTS GUIDE PERSONALIZED FERTILITY TREATMENT DECISIONS IN OVER 180 CLINICS ACROSS 32 COUNTRIES
• ApoGen Biotechnologies — ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapieseventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.

Portfolio highlights

• SeaForester — Restoring the forgotten forests in our ocean.
• Cascadia Seaweed — Cascadia Seaweed cultivates kelp and transforms it into agricultural products that boost yields, cut emissions, and support a healthy planet.
• Ocean Rainforest — Ocean Rainforest offer a collection of premium fully-traceable seaweed products, mostly for food and cosmetic producers.

Portfolio highlights

• Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
• Spica Therapeutics — Spica Therapeutics is a pioneering biotech company dedicated to transforming macrophage biology into breakthrough therapies for patients across multiple therapeutic areas. Leveraging its proprietary functional macrophage fingerprinting technology, Spica identifies and selectively targets disease-relevant macrophage sub
• Primmune Therapeutics — Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.

Portfolio highlights

• Agribuddy — Management of agricultural support application "AGRIBUDDY".
• CanopyLAB — CanopyLAB is an educational technology company located in Hvidovre, Greater Copenhagen, Denmark. We have built an AI-powered social learning platform for corporate training. Through personalization our platform enables all learners to realize their potential in a way that is fast, fun and future-proof. We call it "The Future of Learning-Delivered Today".We work on two verticals:1. The Canopy A social learning platform powered by AI A research-based social learning platform for developing competencies through individualized and adaptive learning experiences. It is designed with an integrated social network structure to enhance collaborative learning and built on strong Nordic learning principles.2. The LAB A learning community with provocative content Join our global learning community for youth. Take free courses, exchange ideas, gain new knowledge and practice competencies offered by 100 + pioneering NGOs in controversial and often neglected topics such as sexuality, sexual & reproductive rights, climate action, health, and the SDGs.CanopyLAB acquired Peruvian publishing startup Yopublico in April 2020.
• Destácame — Destacame is the first behavior-based credit score in Latin America.

Portfolio highlights

• Aurora Analytica — AI-powered clinical intelligence for CROs. Country strategy, feasibility simulation, and trial intelligence in one platform. ESMO-published. EIC-selected. Norway.

Portfolio highlights

• Aurora Analytica — AI-powered clinical intelligence for CROs. Country strategy, feasibility simulation, and trial intelligence in one platform. ESMO-published. EIC-selected. Norway.

Portfolio highlights

• Versor — Versor develops software necessary for true autonomous drone flight both indoors and outdoors, enabling complete automation of industrial drone operations. They believe this level of automation requires superior localization, which is particularly difficult to achieve indoors and in GPS-denied areas. By removing the need for pilots, entire fleetsof drones may be supervised remotely, enabling true scalability of drone operations across various applications.
• Iris.ai — Augment expert knowledge by unifying complex enterprise data to empower next-gen AI agents & applications

Portfolio highlights

• Kure Cells — Kure Cells delivers innovative solutions in cell therapy, biotechnology, and clinical research to advance modern healthcare.

Portfolio highlights

• Entact Bio — Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed tocreate enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.
• SparingVision — We are a genomic medicines company leading a step shift in how ocular diseases are treated. We are going beyond single gene correction therapies to deliver new treatments as quickly as possible to patients affected by Inherited Retinal Diseases (IRDs), regardless of genetic cause.
• March Biosciences — Transforming Patient Care by Unlocking New Target Spaces march.biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity of

Portfolio highlights

• ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
• Sol-Gel Technologies — Sol-Gel designs and delivers innovative dermatological drugs ranging from completely non-leachable to highly-controlled-release of unique formulations and compounds.
• Perspective Therapeutics — Perspective Therapeutics is dedicated to finding the best ways to deliver remedies to patients and their medical needs, and they believe in a targeted, individualized approach to cancer treatment. We design treatments that are given exactly where the doctor needs them.

Portfolio highlights

• Jaakko.com — Reinventing the housing market with no agents, more homes, and less fees.
• Retailgrid — Retailgrid is an AI-powered retail workspace that enables pricing, merchandising, and commercial teams to analyze data, run simulations, and make decisions in real time. Combining a flexible spreadsheet-like interface with AI agents, RetailGrid replaces fragmented tools and manual workflows with a single system for pricing optimization, promotionplanning, and assortment decisions. The platform connects to product, sales, and competitor data, automatically generates insights, and allows teams to test scenarios and deploy decisions at scale. RetailGrid is built for data-driven retailers looking to move faster and operate with the efficiency of top-tier consulting, without the cost or complexity.
• Bahn Express — Bahn Express is a global car transportation company that supports independent contractors while offering quick and easy auto shipping throughout Europe.

Portfolio highlights

• Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
• Ambros Therapeutics — Ambros Therapeutics is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases.
• Reunion Neuroscience — Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

Portfolio highlights

• Iris.ai — Augment expert knowledge by unifying complex enterprise data to empower next-gen AI agents & applications
• Evrotrust — Best way to prove who you are and agree to anything, anywhere. Fully legal, secure and personal. Our mobile first eIDAS solution allows: eID, eSign, eTimestamp, eSeal, eDelivery with the highest status – qualified
• Codery — Codery functions as an Employer of Record (EOR), acting as the official employer for hired professionals. The firm handles the administrative and legal parts of employment, such as registration, payroll, and compliance with local labor laws, allowing enterprises to hire without having to establish regional offices or legal entities.

Portfolio highlights

• Ribbon Bio —
• Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
• TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.

Portfolio highlights

• Delft IMP — Delft IMP (Intensified Materials Production) commercializes nanostructuring of particles using atomic and molecular layer deposition (ALD and MLD), based on the patented and publicized IP and know-how developed within the Product & Process Engineering (PPE) group at Delft University of Technology. Following various feasibility projects betweenindustry and university, Delft IMP was initiated end 2014 to truly commercialize the technology.
• Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.

Portfolio highlights

• Mantle8 — Using bottom-up exploration and decades of geology experience, we are on a mission to deliver natural hydrogen to the world.
• XO Life — XO Life is to build the largest real-world evidence platform for patient insights for all medications and therapies. Together with one of Europe's leading research institutes for patient-centered research, the PROMIS Institute Germany of the Charité, and various pharmaceutical manufacturers, patient experiences are to be recorded in astandardized and systematic manner across a wide range of diseases. Patients are to be enabled to record their therapy course and outcome independently as well as scientifically validated so that these patient insights from real treatment practice can be used in the life science industry and by medical professions.
• Nofence — Manage your livestock from anywhere with GPS collars and a simple app. Unlock more acres, cut fencing costs, and run your operation on your terms.

Portfolio highlights

• APIM Therapeutics — APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress.
• Zelluna Immunotherapy — Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on the development of TCR based immunotherapies.
• Accession Therapeutics — Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells. As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour. Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.

Portfolio highlights

• Kure Cells — Kure Cells delivers innovative solutions in cell therapy, biotechnology, and clinical research to advance modern healthcare.

Portfolio highlights

• Aurora Analytica — AI-powered clinical intelligence for CROs. Country strategy, feasibility simulation, and trial intelligence in one platform. ESMO-published. EIC-selected. Norway.

Portfolio highlights

• Iris.ai — Augment expert knowledge by unifying complex enterprise data to empower next-gen AI agents & applications

Portfolio highlights

• CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
• Lucid Scientific — Lucid Scientific is the maker of Resipher - the world's first handheld cell culture monitor to measure real-time oxygen consumption from inside an incubator.
• Vernal Biosciences — Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis.

Portfolio highlights

• YNMO — YNMO is the first Arabic/English digital solution that aims to improve the quality of care and educational services for individuals with special needs by allowing service providers such as schools, centers & clinics to design and monitor individualized treatment plans.
• Rewaa — Rewaa was founded to make penetrating through the e-commerce industry easier for retailers with minimal operational and marketing costs by solving two main aspects:Marketing aspect: Make in-store products available online. By using Rewaa Cashier System, any product in the physical store will be automatically listed in the online marketplaces andthe merchant's online store. Operational aspects: The integration between physical, online store and marketplace, eliminate the need of independent inventory for online store operations, and that will help to reduce employment cost, therefore, the physical store will be the shipping center, so whenever an order received by online store will be transferred automatically for the nearest branch from the customer. And eventually, the inventory will be automatically updated across all channels.
• Stake — Thousands investors worldwide use Stake to access income-generating real estate deals in high-growth markets, starting from just USD 136

Portfolio highlights

• Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
• Comet Biorefining — Comet Biorefining is a leading provider of sustainable high-quality cost-competitive cellulosic glucose technology for applications in renewable biofuels and biochemicals. The company’s proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosicglucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. Demonstrated at 5 dry tons per day scale, Comet is focusing on commercial scale up and development of commercial partnerships with applications in renewables industries.
• Forth Therapeutics — Forth Therapeutics is a biotechnology company dedicated to advancing precision treatments for fibrosis.